Literature DB >> 9826240

Caffeine and schizophrenia.

J R Hughes1, P McHugh, S Holtzman.   

Abstract

Although the database is small and not completely consistent, it appears that patients with schizophrenia have high caffeine intakes. The reasons are unclear. In nonhumans, caffeine enhances the effects of dopamine, which might be expected to worsen positive symptoms and improve negative symptoms of schizophrenia and worsen tardive dyskinesia. Eliminating caffeine among patients with schizophrenia does not appear to make them better or worse. Acute intake of large amounts of caffeine may increase psychoses and hostility. However, those who chronically use large amounts of caffeine may develop enough tolerance that these adverse effects do not occur, but whether this conjecture is true has not been tested. Interestingly, persons with schizophrenia do not develop anxiety at high doses of caffeine. Although there was initial concern that caffeine might inactivate liquid doses of neuroleptics, the clinical significance of this concern is unclear. On the other hand, caffeine might increase the level of clozapine, and more research in this area is needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826240     DOI: 10.1176/ps.49.11.1415

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  17 in total

1.  Heavy coffee drinking and the risk of suicide.

Authors:  A Tanskanen; J Tuomilehto; H Viinamäki; E Vartiainen; J Lehtonen; P Puska
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Effect of caffeine on clozapine pharmacokinetics in healthy volunteers.

Authors:  S Hägg; O Spigset; T Mjörndal; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 3.  Caffeine Use Disorder: A Comprehensive Review and Research Agenda.

Authors:  Steven E Meredith; Laura M Juliano; John R Hughes; Roland R Griffiths
Journal:  J Caffeine Res       Date:  2013-09

Review 4.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

5.  Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.

Authors:  Marco Matos; Hai-Ying Shen; Elisabete Augusto; Yumei Wang; Catherine J Wei; Yu Tian Wang; Paula Agostinho; Detlev Boison; Rodrigo A Cunha; Jiang-Fan Chen
Journal:  Biol Psychiatry       Date:  2015-02-27       Impact factor: 13.382

6.  Higher serum caffeine in smokers with schizophrenia compared to smoking controls.

Authors:  Kunal K Gandhi; Jill M Williams; Matthew Menza; Magdalena Galazyn; Neal L Benowitz
Journal:  Drug Alcohol Depend       Date:  2010-03-12       Impact factor: 4.492

7.  Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake.

Authors:  Susana Mingote; Mariana Pereira; Andrew M Farrar; Peter J McLaughlin; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-01-17       Impact factor: 3.533

Review 8.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.

Authors:  Sylvain Dubroqua; Benjamin K Yee; Philipp Singer
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

10.  Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.

Authors:  Amy B Adolfo; Christopher G AhnAllen; Jennifer W Tidey
Journal:  Schizophr Res       Date:  2008-11-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.